1. Home
  2. PSO vs STVN Comparison

PSO vs STVN Comparison

Compare PSO & STVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pearson Plc

PSO

Pearson Plc

HOLD

Current Price

$13.95

Market Cap

8.4B

ML Signal

HOLD

Logo Stevanato Group S.p.A.

STVN

Stevanato Group S.p.A.

HOLD

Current Price

$20.88

Market Cap

7.4B

ML Signal

HOLD

Company Overview

Basic Information
Metric
PSO
STVN
Founded
1844
1949
Country
United Kingdom
Italy
Employees
N/A
N/A
Industry
Books
Containers/Packaging
Sector
Consumer Discretionary
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
8.4B
7.4B
IPO Year
2000
2021

Fundamental Metrics

Financial Performance
Metric
PSO
STVN
Price
$13.95
$20.88
Analyst Decision
Buy
Analyst Count
0
4
Target Price
N/A
$25.38
AVG Volume (30 Days)
797.4K
338.7K
Earning Date
01-01-0001
11-06-2025
Dividend Yield
2.34%
0.30%
EPS Growth
31.65
19.61
EPS
0.90
0.60
Revenue
$4,822,578,436.00
$1,373,219,524.00
Revenue This Year
$2.34
$8.42
Revenue Next Year
$5.09
$9.52
P/E Ratio
$14.69
$34.83
Revenue Growth
N/A
6.97
52 Week Low
$12.85
$17.81
52 Week High
$17.90
$28.00

Technical Indicators

Market Signals
Indicator
PSO
STVN
Relative Strength Index (RSI) 64.07 39.09
Support Level $13.03 $20.62
Resistance Level $14.06 $23.88
Average True Range (ATR) 0.13 1.14
MACD 0.14 -0.08
Stochastic Oscillator 89.64 10.68

Price Performance

Historical Comparison
PSO
STVN

About PSO Pearson Plc

UK-listed Pearson is a testing and educational provider. Pearson's primary operations are in assessment and qualification testing and higher education, but they also provide English education and testing, virtual learning, prehiring testing and screening, and upskilling/reskilling. The company divested noncore businesses, including the Financial Times, The Economist, and publishing house Penguin, and is now focused on being an educational resource and testing provider.

About STVN Stevanato Group S.p.A.

Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, the company derives majority revenue from Europe, Middle East and Africa.

Share on Social Networks: